Sinotherapeutics (SH:688247) Sou Hu Cai Jing·2025-12-08 14:37Core Viewpoint - Shanghai Xuantai Pharmaceutical Technology Co., Ltd. has successfully renewed the inclusion of its product, Sitagliptin Metformin Extended-Release Tablets (II), in the National Medical Insurance Directory, which is expected to positively impact the company's long-term operational development despite short-term performance uncertainties [1]. Group 1: Stock Performance - As of December 8, 2025, Xuantai Pharmaceutical (688247) closed at 10.37 yuan, up 0.39% from the previous trading day, with a total market capitalization of 4.701 billion yuan [1]. - The stock opened at 10.36 yuan, reached a high of 10.4 yuan, and a low of 10.3 yuan, with a trading volume of 18.4461 million yuan and a turnover rate of 0.39% [1]. Group 2: Product and Market Impact - The renewed agreement maintains the medical insurance payment standard at 3.47 yuan per tablet, effective from January 1, 2026, to December 31, 2027 [1]. - The product is classified as an oral compound hypoglycemic agent and falls under Category B, which is expected to enhance drug accessibility and market promotion [1].